Published in J Oncol Pract on May 01, 2012
The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med (2014) 1.68
Economic evaluation of genetic screening for Lynch syndrome in Germany. Genet Med (2015) 1.10
Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing. J Genet Couns (2014) 0.76
Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genet Med (2016) 0.76
Lynch syndrome: the patients' perspective. Fam Cancer (2013) 0.75
Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 16.82
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology (1999) 11.94
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39
Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med (2006) 4.95
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med (2009) 3.57
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med (2010) 2.81
Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn (2008) 2.30
Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med (2003) 2.01
The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology (2010) 1.88
Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis (2009) 1.75
The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing. Genet Med (2007) 1.74
Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol (2009) 1.53
Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making (1997) 1.45
Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol (2005) 1.41
Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst (2009) 1.40
Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer (2009) 1.38
Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet (2008) 1.28
Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. Int J Cancer (2001) 1.23
Psychological impact of genetic testing for hereditary non-polyposis colorectal cancer. Clin Genet (2004) 1.22
Lynch syndrome screening implementation: business analysis by a healthcare system. Am J Manag Care (2011) 1.19
Predictive testing for hereditary nonpolyposis colorectal cancer: subjective perception regarding colorectal and endometrial cancer, distress, and health-related behavior at one year post-test. Genet Test (2005) 1.19
Comprehensive genetic counseling for families at risk for HNPCC: impact on distress and perceptions. Genet Test (2002) 1.17
Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res (2010) 1.13
Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer (2008) 1.04
Monitoring coping style moderates emotional reactions to genetic testing for hereditary nonpolyposis colorectal cancer: a longitudinal study. Psychooncology (2008) 1.02
Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health (2008) 0.96
Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med (2005) 0.89
Psychosocial outcome following genetic risk counselling for familial colorectal cancer. A comparison of affected patients and family members. Clin Genet (2008) 0.87
Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer (2012) 0.86
Colonoscopy use following mutation detection in Lynch syndrome: exploring a role for cancer screening in adaptation. Clin Genet (2011) 0.81
Psychological impact of genetic counseling for hereditary nonpolyposis colorectal cancer: the role of cancer history, gender, age, and psychological distress. Genet Test Mol Biomarkers (2010) 0.78
Risk and the pregnant body. Hastings Cent Rep (2009) 4.63
Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A (2002) 4.37
Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med (2005) 3.55
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med (2011) 3.00
Cost utility of prenatal diagnosis and the risk-based threshold. Lancet (2004) 3.00
Optical biopsy of sessile serrated adenomas: do these lesions resemble hyperplastic polyps under narrow-band imaging? Gastrointest Endosc (2013) 2.80
The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest Endosc (2011) 2.51
Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States. Med Care (2002) 2.34
Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence. Med Care (2004) 2.25
Risks, values, and decision making surrounding pregnancy. Obstet Gynecol (2007) 2.11
Trends in colonoscopy for colorectal cancer screening. Med Care (2007) 1.89
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 1.87
Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health (2007) 1.86
Are electronic health records ready for genomic medicine? Genet Med (2009) 1.82
Breast implant-associated anaplastic large cell lymphoma: a systematic review. Plast Reconstr Surg (2015) 1.80
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke (2004) 1.78
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst (2011) 1.71
Colonoscopic treatment of acute diverticular hemorrhage using endoclips. Dig Dis Sci (2007) 1.69
Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2014) 1.65
Mode of delivery: toward responsible inclusion of patient preferences. Obstet Gynecol (2008) 1.57
The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Am J Public Health (2003) 1.53
Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol (2004) 1.52
Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview. Ethn Dis (2005) 1.52
Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Clin Gastroenterol Hepatol (2013) 1.52
Sedation for gastrointestinal endoscopy: new practices, new economics. Am J Gastroenterol (2005) 1.51
Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology (2004) 1.49
Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause (2015) 1.47
Clinical features predicting the detection of abnormalities by double balloon endoscopy in patients with suspected small bowel bleeding. J Gastroenterol Hepatol (2007) 1.46
Decrease in urinary incontinence management costs in women enrolled in a clinical trial of weight loss to treat urinary incontinence. Obstet Gynecol (2012) 1.45
A community-based study of acne-related health preferences in adolescents. Arch Dermatol (2008) 1.44
Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer (2005) 1.43
Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol (2010) 1.32
Rates and predictors of colorectal cancer screening. Prev Chronic Dis (2006) 1.31
The effect of area HMO market share on cancer screening. Health Serv Res (2004) 1.29
How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ (2009) 1.27
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract (2011) 1.21
How the new medicare drug benefit could affect vulnerable populations. Health Aff (Millwood) (2006) 1.21
Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol (2013) 1.16
Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol (2012) 1.16
How does cost matter in health-care discrete-choice experiments? Health Econ (2011) 1.15
An experiment on simplifying conjoint analysis designs for measuring preferences. Health Econ (2003) 1.14
Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis (2007) 1.14
Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract (2010) 1.14
The yield of lower endoscopy in patients with constipation: survey of a university hospital, a public county hospital, and a Veterans Administration medical center. Gastrointest Endosc (2002) 1.13
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol (2006) 1.13
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood (2005) 1.12
Sexual function and aging in racially and ethnically diverse women. J Am Geriatr Soc (2009) 1.11
Visceral obesity as a risk factor for colorectal neoplasm. J Gastroenterol Hepatol (2007) 1.10
Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract (2011) 1.10
Quality and equality in obstetric care: racial and ethnic differences in caesarean section delivery rates. Paediatr Perinat Epidemiol (2009) 1.08
Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med (2011) 1.07
Education does pay off: pneumococcal vaccine screening and administration in hospitalized adult patients with pneumonia. J La State Med Soc (2004) 1.06
Women's out-of-pocket expenditures and dispensing patterns for oral contraceptive pills between 1996 and 2006. Contraception (2010) 1.06
"I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction. Ethn Dis (2005) 1.04
What parents want to know about the storage and use of residual newborn bloodspots. Am J Med Genet A (2014) 1.04
Moving beyond the typologies of managed care: the example of health plan predictors of screening mammography. Health Serv Res (2004) 1.03
A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics (2009) 1.01
Complications of endovascular repair of high-risk and emergent descending thoracic aortic aneurysms and dissections. J Vasc Surg (2004) 1.00
Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services. Am J Manag Care (2004) 0.97
Optobiology: optical control of biological processes via protein engineering. Biochem Soc Trans (2013) 0.97
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol (2007) 0.97
Obstetricians' attitudes and beliefs regarding umbilical cord clamping. J Matern Fetal Neonatal Med (2013) 0.97
Disparities in cancer screening in individuals with a family history of breast or colorectal cancer. Cancer (2011) 0.95
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
Clinical and economic burden of emergency department visits due to gastrointestinal diseases in the United States. Am J Gastroenterol (2013) 0.94
Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Aff (Millwood) (2006) 0.94
Social and familial context of prenatal genetic testing decisions: are there racial/ethnic differences? Am J Med Genet C Semin Med Genet (2003) 0.94
Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med Reconstr Surg (2011) 0.93
Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screening. Prev Chronic Dis (2007) 0.92
Medicine or Surgery (Ms): a randomized clinical trial comparing hysterectomy and medical treatment in premenopausal women with abnormal uterine bleeding. Control Clin Trials (2004) 0.92
Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities. Cancer (2012) 0.92
Proximal and distal colorectal cancer resection rates in the United States since widespread screening by colonoscopy. Gastroenterology (2012) 0.91
Assessment of demand for prenatal diagnostic testing using willingness to pay. Obstet Gynecol (2004) 0.91
Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine (Lond) (2012) 0.91
Finding autonomy in birth. Bioethics (2009) 0.91
Patient costs for medication abortion: results from a study of five clinical practices. Womens Health Issues (2006) 0.91
Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol (2009) 0.91
Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol (2005) 0.91
Effects of changes in prenatal aneuploidy screening policies in an integrated health care system. Obstet Gynecol (2013) 0.90
The Association of Expanded Access to a Collaborative Midwifery and Laborist Model With Cesarean Delivery Rates. Obstet Gynecol (2015) 0.90
Management of the low-grade abnormal Pap smear: What are women's preferences? J Fam Pract (2002) 0.90
Is the prevalence of gatekeeping in a community associated with individual trust in medical care? Med Care (2003) 0.90
Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care (2011) 0.90
Development and validation of a sexual functioning measure for use in diverse women's health outcome studies. Am J Obstet Gynecol (2008) 0.89
Perceived risk of prenatal diagnostic procedure-related miscarriage and Down syndrome among pregnant women. Am J Obstet Gynecol (2008) 0.89
Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol (2010) 0.89
Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Cancer Causes Control (2004) 0.88
Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack. JAMA (2012) 0.88
Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf (2007) 0.88
Melanosis coli. Clin Gastroenterol Hepatol (2008) 0.87
Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med (2009) 0.87
Medicare formulary coverage for top-selling biologics. Nat Biotechnol (2009) 0.87
Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol (2008) 0.86
Understanding risk, patient and provider preferences, and obstetrical decision making: approach to delivery after cesarean. Semin Perinatol (2010) 0.86
Colorectal cancer screening differential costs for younger versus older Americans. Am J Prev Med (2006) 0.86